Get started
Work

Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Year: 2023
Type: supplementary-materials
Abstract: PDF file - 70KB, Supplementary Table 2. Grade 3/4 Adverse Events that Occurred in ≥2% of Patients.
DOI: 10.1158/1078-0432.22448583
Authors: Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia M. LoRusso
Language: English
Open Access status: gold
OpenAlex ID: W4362394564
Cites:
Cited by:
Related to: 10